The rehabilitation room at Huanhu Hospital in Tianjin holds a treadmill, a frame of motors and a stimulator that fires into the lower back. A stroke survivor imagines lifting a foot; the frame lifts it.
What allowed that experiment to begin was not a device certificate. It was a filing, lodged days after two hospital committees signed off.
China has now written that route into law.
Key takeaways
- State Council Order 818 took effect on 1 May 2026, creating a filing route for techniques that are neither drugs nor devices (State Council).
- Studies need a tertiary-A hospital, academic and ethics review, then national filing within five working days (Order 818, Article 15).
- Subjects cannot be charged; paid clinical use needs separate approval (Articles 20 and 29).
- A companion rule sends anything meeting the device definition back to device registration, barring that route (NHC and NMPA, 2026).
- By the eighth batch on 11 September 2026, 103 projects had filed; 95 were existing studies re-filed under Article 57 (The Paper).
What filed, and what it is not
On 5 November 2026, a project run by Tianjin University's Haihe Laboratory for brain–computer interaction (脑机接口) and Huanhu Hospital completed a filing with the National Health Commission. It combines spinal cord stimulation, a non-invasive brain–computer interface and a hybrid exoskeleton for lower-limb impairment in chronic stroke patients who have stopped improving on conventional rehabilitation. Suishi (Tianjin) Intelligent Technology (燧世智能) and Beijing PINS Medical (品驰医疗) co-produced the hardware, called Shengong–Shenchi (神工-神驰).
Tianjin's government described it as the first non-invasive BCI clinical research project to complete this filing since the regulation took effect in May 2026.
Three things it is not: a device approval, payment, or a first for neurotechnology as a whole — the claim is scoped to non-invasive BCI.
Four doors, one of them new
A medical technology reaches Chinese patients through one of four entrances: a drug authorisation, a device registration, an emergency-use permission, or — the newest — a clinical research filing followed by a conversion approval.
State Council Order 818 (国务院令第818号), passed in September 2025 and in force since 1 May 2026, opened the fourth. It runs to seven chapters and 58 articles, and defines a biomedical new technology (生物医学新技术) as a clinical measure that uses biological principles, acts at the cellular or molecular level, and has not been applied clinically in China.
The reason to care is timing: device registration reviews a product largely outside the hospital, while this route starts inside one and can begin before any product is approved.
Inside the filing route
Why the route suits hospital-led work:
- The sponsor must be a legal person established in China and must first show safety and efficacy in laboratory and animal work (Articles 10 and 9).
- The host must be a tertiary-A hospital (三级甲等医院) with academic and ethics committees, qualified staff and stable funding (Article 11).
- The institution files within five working days of both reviews passing; the commission publishes the list and may order a protocol change, suspension or termination (Articles 15 and 17).
- Subjects may not be charged, devices used in the study must still satisfy device rules, and records are kept 30 years (Articles 20 to 22).
- If a subject is harmed, treatment costs fall on the sponsor unless the institution was at fault (Article 27).
Conversion is a separate decision. The commission refers the file for technical and ethical assessment within five working days and decides within 15 working days of receiving it (Articles 29 and 31). Review is prioritised for seriously life-threatening conditions with no effective treatment (Article 32). Only after approval may institutions charge for clinical use (Article 34).
The boundary rule is the real text
The document that decides which door a product takes is a companion rule: the guidelines on delineating biomedical new technologies from drugs and devices, issued by the health commission with the drug regulator and effective the same day.
Its logic is narrow. Anything meeting the definition of a medical device must go through device registration and cannot use the new-technology conversion route. The route is reserved for techniques that are hard to develop as a device, highly personalised, and for conditions where no drug with the same mechanism is approved or in a confirmatory trial.
The filing list covers five families: gene therapy, cell and derivative therapy, tissue and organ therapy, microbial therapy, and brain–computer interfaces.
What is filed is the procedure, not the product: a hospital can hold an approved technique while the hardware inside it carries ordinary device obligations.
The first four months were mostly transfers
By the eighth published batch on 11 September 2026, the National Centre for Biotechnology Development had listed 103 filed projects. Of those, 95 were studies already running under earlier stem-cell and somatic-cell frameworks, re-filed under Article 57, which gave existing projects one month to register. Eight were counted as new (The Paper, September 2026).
Read the ratio, not the total. The machinery was built fast — eight batches in four months — but new inflow is thin; even among the eight, some re-applied studies previously filed at a lower tier.
The register is the useful artefact: it names the hospital, the sponsor and the project, batch by batch.
Honest limitations
I have read the regulation text and published summaries of the delineation guidelines, not the conversion-approval work rules, which run to 26 articles. The Tianjin project has no public protocol, enrolment target or endpoint. No project has publicly completed the conversion step, so the paid end of the route is untested. The 95-and-8 split is a newsroom analysis of official lists, not a government tally. And the definition's cellular framing sits more naturally on cell therapy than on electrical stimulation; how it is applied to neuromodulation is unpublished.
What readers can do now
- Ask a Chinese partner which route a technique is filed under. Filing numbers follow the pattern MR-N-province-2026-0000NN and appear in public lists.
- Test the delineation rule against your own product: standardisable and mass-producible points to devices, personalised and hospital-delivered to the technology route.
- Read the monthly filing lists for competitors. They name the hospital and the sponsor, a firmer signal of intent than a press release.